Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $978467.0.

  • Revolution Medicines' Gains from Sales and Divestitures rose 3496.75% to $978467.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $978467.0, marking a year-over-year increase of 3496.75%. This contributed to the annual value of $1.0 million for FY2024, which is 7526.87% up from last year.
  • Latest data reveals that Revolution Medicines reported Gains from Sales and Divestitures of $978467.0 as of Q3 2025, which was up 3496.75% from $633511.0 recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Gains from Sales and Divestitures peaked at $1.0 million during Q4 2024, and registered a low of $1798.0 during Q1 2021.
  • In the last 5 years, Revolution Medicines' Gains from Sales and Divestitures had a median value of $260143.0 in 2023 and averaged $335960.6.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 454069.01% in 2021, then surged by 3496.75% in 2025.
  • Quarter analysis of 5 years shows Revolution Medicines' Gains from Sales and Divestitures stood at $78010.0 in 2021, then surged by 257.45% to $278848.0 in 2022, then surged by 106.91% to $576974.0 in 2023, then soared by 75.27% to $1.0 million in 2024, then dropped by 3.24% to $978467.0 in 2025.
  • Its last three reported values are $978467.0 in Q3 2025, $633511.0 for Q2 2025, and $271536.0 during Q1 2025.